Business Context and Reporting Period
This Form 8-K was filed by Tokai Pharmaceuticals, Inc. on March 8, 2017. The report addresses a regulatory deficiency regarding the company's stock listing status on the Nasdaq Global Select Market. Note: The request metadata references "Eledon Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Tokai Pharmaceuticals, Inc."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the bid price for the Company's common stock closed below the minimum $1.00 per share requirement for the last 30 consecutive business days.
Material Changes
The material change reported is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. This notification confirms that the Company failed to meet the minimum bid price requirement ($1.00 per share) for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending September 4, 2017, to regain compliance.
- Regaining Compliance: To cure the deficiency, the stock must close at $1.00 or more for a minimum of 10 consecutive business days before the compliance deadline.
- Alternative Options: If the Company fails to regain compliance by the deadline, it may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market, subject to meeting other listing standards and paying an application fee.
- Delisting Risk: If the Company does not regain compliance and is not eligible for an additional period, the stock may be delisted. The Company may appeal such a determination to a NASDAQ Listing Qualifications Panel, though success is not assured.
- Management Action: Management intends to monitor the closing bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of Tokai Pharmaceuticals, Inc. common stock to assess progress toward the $1.00 threshold.
- Confirm whether the Company has announced a reverse stock split or other corporate action to address the bid price deficiency.
- Monitor official Nasdaq communications for updates on the Company's compliance status or potential transfer to the Nasdaq Capital Market.
- Review subsequent filings for any updates on the appeal process if a delisting determination is issued.